BR112021022876A2 - Método para descolonizar candida auris de uma área anatômica de um sujeito - Google Patents

Método para descolonizar candida auris de uma área anatômica de um sujeito

Info

Publication number
BR112021022876A2
BR112021022876A2 BR112021022876A BR112021022876A BR112021022876A2 BR 112021022876 A2 BR112021022876 A2 BR 112021022876A2 BR 112021022876 A BR112021022876 A BR 112021022876A BR 112021022876 A BR112021022876 A BR 112021022876A BR 112021022876 A2 BR112021022876 A2 BR 112021022876A2
Authority
BR
Brazil
Prior art keywords
decolonize
candida auris
subject
anatomical area
enfumafungin
Prior art date
Application number
BR112021022876A
Other languages
English (en)
Portuguese (pt)
Inventor
A Angulo Gonzalez David
Andrew Barat Stephen
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of BR112021022876A2 publication Critical patent/BR112021022876A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR112021022876A 2019-05-16 2020-05-12 Método para descolonizar candida auris de uma área anatômica de um sujeito BR112021022876A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962849019P 2019-05-16 2019-05-16
PCT/US2020/032547 WO2020232037A1 (en) 2019-05-16 2020-05-12 Antifungal agents, like ibrexafungerp for candida auris decolonization

Publications (1)

Publication Number Publication Date
BR112021022876A2 true BR112021022876A2 (pt) 2022-04-12

Family

ID=70861571

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022876A BR112021022876A2 (pt) 2019-05-16 2020-05-12 Método para descolonizar candida auris de uma área anatômica de um sujeito

Country Status (14)

Country Link
US (1) US20220211684A1 (cg-RX-API-DMAC7.html)
EP (1) EP3968986A1 (cg-RX-API-DMAC7.html)
JP (2) JP7770191B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220009416A (cg-RX-API-DMAC7.html)
CN (1) CN113905733A (cg-RX-API-DMAC7.html)
AU (1) AU2020276595B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021022876A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140637A1 (cg-RX-API-DMAC7.html)
EA (1) EA202193146A1 (cg-RX-API-DMAC7.html)
IL (1) IL288165B2 (cg-RX-API-DMAC7.html)
MA (1) MA55958A (cg-RX-API-DMAC7.html)
MX (1) MX2021013899A (cg-RX-API-DMAC7.html)
TW (2) TW202602460A (cg-RX-API-DMAC7.html)
WO (1) WO2020232037A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102980640B1 (ko) 2023-07-03 2026-06-24 연세대학교 산학협력단 칸디다 아우리스에 대한 항진균제 스크리닝 방법 및 항진균용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
BRPI0912074B1 (pt) * 2008-08-12 2021-08-03 Merck Sharp & Dohme Corp Composto e composição farmacêutica
ES2955711T3 (es) * 2016-03-16 2023-12-05 Cidara Therapeutics Inc Regímenes de dosificación para el tratamiento de infecciones fúngicas
JP7263313B2 (ja) * 2017-04-10 2023-04-24 サイネクシス,インコーポレーテッド 併用される抗真菌剤
WO2018213641A1 (en) * 2017-05-17 2018-11-22 T2 Biosystems, Inc. Nmr methods and systems for the rapid detection of candida species
PL3661503T3 (pl) * 2017-08-04 2023-01-09 Scynexis, Inc. Środki przeciwgrzybicze o zwiększonej aktywności przy kwasowym odczynie ph
MA54866A (fr) * 2019-01-30 2022-05-04 Scynexis Inc Antifongiques triterpénoïdes pour le traitement d'infections ostéoarticulaires fongiques

Also Published As

Publication number Publication date
MX2021013899A (es) 2022-02-10
IL288165B1 (en) 2026-01-01
JP7770191B2 (ja) 2025-11-14
EA202193146A1 (ru) 2022-02-11
TWI881977B (zh) 2025-05-01
IL288165A (en) 2022-01-01
WO2020232037A1 (en) 2020-11-19
JP2022532734A (ja) 2022-07-19
CN113905733A (zh) 2022-01-07
MA55958A (fr) 2022-03-23
IL288165B2 (en) 2026-05-01
AU2020276595B2 (en) 2025-12-04
JP2025118765A (ja) 2025-08-13
TW202110441A (zh) 2021-03-16
CA3140637A1 (en) 2020-11-19
AU2020276595A1 (en) 2021-12-09
TW202602460A (zh) 2026-01-16
US20220211684A1 (en) 2022-07-07
EP3968986A1 (en) 2022-03-23
KR20220009416A (ko) 2022-01-24

Similar Documents

Publication Publication Date Title
CR20220545A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
CO2022000481A2 (es) Inhibidores de enzimas
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
ZA202210530B (en) Personal care compositions
BR112021017620A2 (pt) Compostos macrocíclicos
SA519400913B1 (ar) تركيبة موضعية لتعزيز إلتئام الجروح
BR112022011690A2 (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer, método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas e invenção
AR112482A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry
BR112022010441A2 (pt) Análogos de equinocandina e método de preparação para os mesmos
MX2022003845A (es) Tratamientos cognitivos medicinales.
BR112023006312A2 (pt) Composto, métodos para preparar o composto, composição farmacêutica e uso do composto
CO2023012342A2 (es) Inhibidores de enzimas
CL2025002366A1 (es) Compuesto que contiene trifluorometilsulfonilo.
CL2023003240A1 (es) Cepas bacterianas con actividad fungicida, composiciones que las comprenden y uso de las mismas
WO2022099187A3 (en) Sars-cov-2 antigen-binding proteins and uses thereof
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca
MX2023009676A (es) Extractos de corteza de abedul que contienen betulina y su formulacion.
MX2021013899A (es) Agentes antifungicos para la descolinizacion de candida auris.
JOP20250074A1 (ar) تركيبة دالبافانسين سائلة
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas
BR102020012866A8 (pt) Composições tópicas contendo derivados de n-acil-dipeptídeo e ácido glicólico

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]